Coreg is used for treating hypertension, left ventricular dysfunction and congestive heart failure. Credit: Steve Buissinne from Pixabay.

The US Federal Circuit Court of Appeals in Washington, DC has reinstated a 2017 ruling that Teva Pharmaceutical should pay $235.5m to GlaxoSmithKline (GSK) for inducing infringement of a patent covering GSK’s heart drug Coreg.

GSK holds US approval for the sale of Coreg (carvedilol), an alpha-/beta-adrenergic blocker used to treat left ventricular dysfunction following myocardial Infarction, hypertension and congestive heart failure.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In a 2-1 decision, the majority panel at the Circuit Court found substantial evidence that Teva prompted doctors to recommend its generic tablets to treat medical conditions covered by a GSK patent, according to Reuters.

Teva, in a statement reported by the news agency, said it was disappointed with the outcome and plans to appeal and introduce additional defences. The company added that it did not engage in patent infringement.

Teva started marketing a Coreg generic in 2007 with ‘skinny’ labels indicating treatment for the left ventricular dysfunction and hypertension.

In 2011, the US Food and Drug Administration (FDA) required Teva to amend its label to be identical in content to the approved GSK labelling.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Teva then updated its label to include the indication for the treatment of congestive heart failure.

GSK, with patent expired in 2015, filed a lawsuit against Teva for ‘induced infringement’ in 2014.

A Delaware jury ruled that Teva should pay $234.1m for lost profit, along with $1.4m in royalties, but US District Judge Leonard Stark overturned the verdict.

Stark said that other factors could have prompted doctors to prescribe the generic.

Circuit Judge Pauline Newman concluded last week that promotional materials, press releases, product catalogues, the FDA labels and witness testimony supported the earlier verdict for Teva’s induced infringement of GSK’s patent.